Skip to Main Content

Beam Therapeutics, a company focused on genome editing, is in a strange situation.

The firm’s stock price has roughly quadrupled since the fall, and not because of pivotal data or an affirmational partnership but rather because of a broad and quite likely temporary boom for companies involved in editing DNA. But unlike some of its contemporaries, Beam isn’t letting its moment go to waste.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!